cyrilzakka/clinical-trials huggingface dataset:
Comparative Effects of Aerobic and Aviva Exercises in Primary Dysmenorrhea

Primary dysmenorrhea is a cramping pain in the lower abdomen occurring just before or during menstruation without pelvic pathology. Primary dysmenorrhea is not a life-threatening condition and does not cause organ failure. However, it can affect the quality of life of women and cause inability to carry out daily functioning consequently, absence from school or workplace. Exercise is one of the non-conservative methods to reduce the severity of primary dysmenorrhea. The aim of this study is to compare the effects of aerobic and Aviva exercises on primary dysmenorrhea. This study emphasizes the importance of aerobic exercises and Aviva exercise to reduce the severity of primary Dysmenorrhea. This will help in patients over all recovery and will improve general well-being.

This will be a Randomized clinical trial conducted on 42 participants. The data will be collected from Sharif Medical Complex and Kasrat Gym Lake City by using non-probability convenience sampling technique. Patients with primary dysmenorrhea diagnosed with Walid score questionnaire of age 20-40 will be included. A sample will be divided into two groups, each group will have 21 participants. The group A will be given Aerobic exercise and Group B will be given Aviva exercises. Participants will be assessed using the Mc Gill pain questionnaire for pain, women health initiative insomnia rating scale will be used for sleep, and brief pain inventory short form for daily functioning and Quality of life enjoyment and satisfaction questionnaire short form for quality of life. Data will be analyzed by using SPSS version 26.0.


Eligibility Criteria:
Inclusion Criteria:

* Unmarried females
* Regular menstrual cycles (every 21-35 days)
* Moderate to severe menstrual cramp pain

Exclusion Criteria:

* Pelvic pathology (endometriosis, chronic pelvic inflammatory disease, adenomyosis)
* History of pelvic surgery or inflammatory disease
* Chronic pain or pain disorders (e.g., fibromyalgia)
* Current use of pain medication or muscle relaxants
* History of mental health disorders (e.g., depression, anxiety)
* Inability to understand or complete study assessments
* Any underlying medical condition that may be contributing to dysmenorrhea (e.g., thyroid disorders, kidney disease)
Treatment of Gingival Recession Using Mesenchymal Stem Cells

Treatment of patients with gingival recession by injection of autologous adipose-derived mesenchymal stem cells mixed with collagen gel

Treatment of patients with gingival recession by injection of autologous adipose-derived mesenchymal stem cells mixed with collagen gel (1×106cells/0.2 ml). The volume of the mixture is divided into 4 equal injections in the gingival region of one tooth (one place injection volume is 0.05 ml of mixture).

Eligibility Criteria:
Inclusion Criteria:

-gingival recession

Exclusion Criteria:

* pregnancy
* breast-feeding
* acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis
* mental disorders
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

This partially randomized, multi-center parallel-group study will evaluate the safety, pharmacokinetics and the effect on viral load and viral shedding of Tamiflu (Oseltamivir) in patients with influenza. Adult and adolescent patients will be randomized to receive either 100 mg or 200 mg of study drug intravenously every 12 hours. Investigators and patients are blinded to knowledge of the assigned dose of Tamiflu. There is an option to convert to oral Tamiflu after 6 intravenous infusions. The anticipated time on study treatment is 5 days, with an optional treatment extension of a further 5 days, if necessary. There will be a non-randomized, open-label treatment group for patients with moderate/severe renal impairment or renal failure. Intravenous dose levels and frequency will be adjusted appropriately to their renal situation.


Eligibility Criteria:
Inclusion Criteria:

* Adult and adolescent patients, 13 years of age and older
* Diagnosis of influenza
* ≤ 144 hours between the onset of influenza-like illness and first dose of study drug

Non-randomized, open-label treatment group:

* Patients with moderate/severe renal impairment or renal failure with creatinine clearance 10-60 mL/min

Exclusion Criteria:

* Clinical evidence of severe hepatic decompensation at the time of randomization
* Acute ischemia or significant arrhythmia
Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer

This is an observational study in which a questionnaire is used to obtain quality of life data after patients undergo a hypo-fractionated course of stereotactic body radiotherapy (SBRT) for the treatment of their prostate cancer. The SBRT itself is considered standard of care for these patients and as such, is not an official component of the study.


Eligibility Criteria:
Inclusion Criteria:

* Eligible patients will have clinical stage T1c, T2a, or T2b, a pre-biopsy PSA level \<10 ng/mL and a biopsy Gleason score of 3+3 (or 3+4 if fewer than 30% of biopsy cores are involved).
* The ability to understand and willingness to sign a written informed consent are necessary.

Exclusion Criteria:

* Patients with tumor parameters that fall outside of the inclusion criteria.
* Patients with evidence on imagining (bone scan, CT, or MRI) suggestive of disseminated disease.
* Patients who have had any form of prior prostate treatment (surgery, radiotherapy, cryotherapy, high intensity focused ultrasound, TURP).
* A prior course of hormone therapy (androgen deprivation) of greater than 3 months duration.
* The use of other concurrent investigational agents.
* There are no exclusions due to co-morbid disease or illnesses except for patients with severe inflammatory bowel disease.
* No life expectancy restrictions will apply.
* Performance status will not be considered.
Brief Intervention and/or Distribution of Free Condoms for Travelers

The objective of this study is to assess the impact of a structured intervention and/or free distribution of condoms during the pre-travel consultation on sexual risk behavior of young persons traveling alone.

All persons aged 18 - 44 years planning to travel alone and attending the travel clinic of the Medical Outpatient Clinic in Lausanne will be asked to participate. The subjects will be randomized into three groups: 1. no intervention, 2. free condoms without further explanations, 3. a structured intervention of 5 minutes on STI risk reduction plus free condoms. The structured interventions will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The subjects will complete a pre-travel questionnaire prior to the medical consultation. A post-travel questionnaire will be sent to them 10 days after their trip. The questionnaires will include questions on demographic characteristics, sexual habits, alcohol/tobacco/marijuana consumption and sexual relationships during the trip.

Eligibility Criteria:
Inclusion Criteria:

* Age: 18 - 44 years
* Travelling without the regular partner

Exclusion Criteria:

* Refusal of patient to participate
REMISE Study: REMnant Biospecimen Investigation in SEpsis

In the REMISE is study, we will compare blood proteins, biomarkers, and other -omics prospectively collected from patients with sepsis from two sources, i.) remnant (discarded) samples from the clinical laboratory, and ii.) prospectively collected in UPMC Presbyterian hospital research coordinator specimen collected biospecimens.

Analyses will include traditional biomarkers, quantitative proteomics, metabolomics, lipidomics, transcriptomics, and pathogen genomic sequencing in both sets of samples. This data will allow the assessment of the feasibility, integrity, and scientific value of remnant samples compared to research coordinator samples collected at the bedside for mechanistic sepsis research.


Eligibility Criteria:
Inclusion Criteria:

* Adult patient, at least 18 years of age
* Meeting Sepsis-3 criteria within 6 hours of admission
* Biospecimens obtained for routine clinical care and measurement
* Peripheral intravenous access

Exclusion Criteria:

* Patients who do not have Sepsis-3
* Traumatic injury,
* Inability to consent or contact legal representative,
* Cardiac arrest,
* Stroke,
* Comfort measures only,
* Unable to obtain intravenous access, and/or
* Subject declines to participate.
* No residual blood left in clinical sample
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma

The purpose of this study is that ruxolitinib may be a possible treatment option for relapsed or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma.

Patients will take ruxolitinib 20 mg orally twice a day, 40mg in total per day, for 4 weeks.4 weeks is 1 cycle. Treatment will be continued until documented disease progression or unacceptable toxicity and the maximum period of treatment is 16 cycles.

Eligibility Criteria:
Inclusion Criteria:

* Histologically proven Hodgkin lymphoma or primary mediastinal large B-cell lymphoma
* Patient should belong to any one of following clinical situations A.Patient who are not able to get autologous stem cell transplantation after relapsing the salvage chemotherapy B. Relapsed after autologous stem cell transplantation C. Refractory to salvage chemotherapy or autologous stem cell transplantation
* Adequate organ function as defined by the following criteria:

A. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤2.5 x local laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if liver function abnormalities are due to underlying malignancy B. Total serum bilirubin ≤1.5 x ULN C. Absolute neutrophil count (ANC) ≥ 1500/µL D. Platelets ≥ 100,000/µL E. Hemoglobin ≥ 9.0 g/dL (may be transfused or erythropoietin treated) F. Serum calcium ≤ 12.0 mg/dL G. Serum creatinine ≤ 1.5 x ULN

* At least one measurable lesion
* ECOG PS 0-2
* Informed consent
* Age from 19 to 80

Exclusion Criteria:

* Previously received allogeneic stem cell transplantation
* History of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease or secondary CNS involvement on CT or MRI scan.
* Currently uncontrolled active infection
* Previous history of recurrent herpes zoster or recurrent tuberculosis
* Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2.
* Pregnant or lactating females or patients who ar not willing to use an adequate method of birth control for the duration of the study
Active Warming in Prehospital Trauma Care

Prevention and treatment of hypothermia by active warming in prehospital trauma care is recommended but scientifical evidence of its effectiveness in a clinical setting is scarce. The objective of this study was to evaluate the effect of additional active warming during road or air ambulance transportation of trauma patients.

Patients were assigned to either passive warming with blankets or passive warming with blankets with the addition of an active warming intervention using a large chemical heat pad applied to the upper torso. Ear canal temperature, subjective sensation of cold discomfort and vital signs were monitored.

Mean core temperatures increased from 35.1°C (95% CI; 34.7-35.5 °C) to 36.0°C (95% CI; 35.7-36.3 °C) (p\<0.05) in patients assigned to passive warming only (n=22) and from 35.6°C (95% CI; 35.2-36.0 °C) to 36.4°C (95% CI; 36.1-36.7°C) (p\<0.05) in patients assigned to additional active warming (n=26) with no significant differences between the groups. Cold discomfort decreased in 2/3 of patients assigned to passive warming only and in all patients assigned to additional active warming, the difference in cold discomfort change being statistically significant (p\<0.05). Patients assigned to additional active warming also presented a statistically significant decrease in heart rate and respiratory frequency (p\<0.05).

In mildly hypothermic trauma patients, with preserved shivering capacity, adequate passive warming is an effective treatment to establish a slow rewarming rate and to reduce cold discomfort during prehospital transportation. However, the addition of active warming using a chemical heat pad applied to the torso will significantly improve thermal comfort even further and reduce the cold induced stress response.


Eligibility Criteria:
Inclusion Criteria:

* Subjects were sequential trauma patients, age ≥ 18 years, who had sustained an injury outdoors and were transported by one of the participating EMS units.

Exclusion Criteria:

* Patients were excluded if initial level of consciousness was affected, (Glasgow Coma Scale \< 15), if they required prehospital CPR or if duration of transportation was expected to be shorter than 10 minutes.
* As the aim of the study was to investigate the effect of active warming intervention in cold stressed patients, those patients who had already received active warming or had been taken indoors for more than 10 minutes before EMS unit arrival or had an initial cold discomfort rating ≤ 2 were also excluded.
Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF

Despite the large therapeutic arsenal available since one decade allowing a strong reduction of inflammation process, rheumatoid arthritis (RA) patients claimed pain, fatigue, sleep problems and other quality of life outcomes. Fatigue reduction during TNF blockers therapy is lower than the strong reduction in RA disease activity. Furthermore, RA patients have higher prevalence of non-inflammatory pain than general population. Fatigue is a real major problem due to 50% of patients considered it as severe.

This dissociation between disease activity and fatigue level suggests that fatigue is multifactorial. No consistent explanations for fatigue are currently available.


Eligibility Criteria:
Inclusion Criteria :

* RA diagnosis according to ACR/EULAR 2010
* RA with low disease activity according to DAS28 \< 3.2
* Written consent obtained

Exclusion Criteria :

* Other diagnosis than RA
* Depression known
* Hypertension treated or not,
* Diseases interfering with ANS analysis: cardiac arrhythmia, beta-blocker therapy,
* Pregnant or breastfeeding women,
* Inability to go two consecutive days at the North hospital for the delivery and return of the Vista02 device
Evaluating Technologies for Point-of-Care Blood Collections by Patients

A study evaluating technologies for point-of-care use in clinical trials.

A study evaluating the Tasso+ blood collection device that enables the safe and convenient collection of blood by a lay person (eg, patient or study participant) under the supervision of an Health Care Provider.

Eligibility Criteria:
Inclusion Criteria:

* Male or female adults (18 years of age or older, inclusive), at the time of informed consent. Participants who are deemed pregnant by urine pregnancy test at Screening remain eligible.
* Able to understand and willing to provide informed consent and able to comply with the study procedures and restrictions.
* Participant considered healthy or in well-compensated health according to medical history, concomitant medications, and physical examination (including vital signs).

Exclusion Criteria:

* Medical history, or physical examination (including vital signs) findings, that suggest to the Investigator that the participant has undiagnosed or untreated medical condition(s) that could confound the AE evaluation and thereby undermine the study objectives.
* Any known medical history of infection with HIV (CD4\<200 and/or detectable viral load within the prior 3 months), hepatitis B (positive HBsAg), or hepatitis C (positive hepatitis C virus antibody).
* Chronic illness for which a participant's immune system is suspected by the Investigator to be impaired or altered, such as cancer, autoimmune conditions, and diabetes.
* Participation in another investigational study within 30 days of time of consent or plans to do so during the course of this study.
* Large tattoos or skin eruptions overlying either of the deltoid muscles that could confound the monitoring for local reactogenicity following Tasso+™ administrations.
* Use of systemic immunomodulatory therapy, including oral corticosteroids, within the past 6 months; or planned use of medications or nutritional supplements known to or which potentially could affect organ function within 30 days prior to screening until end of study.
* Acute illness within 14 days prior to device use unless it is determined by the Investigator that the illness is mild in severity and unlikely to progress.
* Of limited legal capacity.
* Any condition (including suspected alcohol- or drug-related addiction) that precludes adequate understanding, cooperation, and/or compliance with study procedures or any condition that could pose a risk to the participant's safety per Investigator judgment.
Cycloplegic Delivery Investigation

The goal of this study is to compare the effectiveness of the administration of sequential drops, a combination drop and a combination spray for producing mydriasis and cycloplegia.


Eligibility Criteria:
Inclusion Criteria:

* patients ages 8 to 30 with best corrected acuity of 20/30 or better in both eyes at distance and near will be recruited.

Exclusion Criteria:

* vision not correctable to 20/30 or better
Energy-Harvesting Mesofluidic Impulse Prosthesis: e-MIP

The purpose of this research is to validate the e-MIP design and function by testing the ability of e-MIP to harvest energy and return a sufficient amount of energy to assist the user during gait. The investigators will also evaluate whether prosthetic users are able to wear and use the e-MIP device long-term.


Eligibility Criteria:
Inclusion Criteria:

* Unilateral transtibial amputation
* At least twelve months post-amputation
* Currently walking on a prosthesis for at least one year
* Uses modular endoskeletal prosthetic components
* Has bilateral normal range of motion
* Ability to walk independently and for an extended length of time (walking ability of each individual will be assessed by the principal investigator or study prosthetist during the recruitment period)
* Ability to communicate individual perceptions
* Ability to provide informed consent

Exclusion Criteria:

* Confounding injury or musculoskeletal problem
* Pregnancy
* Lower limb peripheral neuropathy
* Symptomatic cardiovascular disease or chronic obstructive pulmonary disease
* Not able to read and understand English
The Effect of Acupressure on Preoperative Anxiety and Postoperative Pain and Nausea-Vomiting

The study was conducted in the ENT Clinic of Mersin Şehir Training and Research Hospital between June 1 and December 1, 2021, with a total of 60 adult patients, 30 in the study group and 30 in the control group, who met the inclusion and exclusion criteria.

In the study, 60 patients were randomly assigned to the study and control groups. The study group (n = 30) included Shen Men, the 7th acupuncture point (HT7) of the heart meridian located between the ulna and pisiform bones on the radial side of the flexor carpi ulnaris tendon, EX-HN3 (Yintang) located in the middle of the beginning of both eyebrows and the thumb and the LI4 points located in the space between the index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied for an average of 15 minutes. No intervention didn't made to the control group (n = 30). The primary outcome of the study is the effect of acupressure on the state and trait anxiety level of patients. The secondary outcome of the study is the effect of acupressure on pain and nausea and vomiting level in patients. Anxiety levels of the patients were evaluated before and 15 minutes after acupressure application; pain levels were evaluated at the 4th postoperative hour, before going to bed at night (22.00), waking up in the morning (08.00) and at discharge; nausea and vomiting levels were evaluated in the first 24 hours after surgery.

Eligibility Criteria:
Inclusion Criteria:

* Emergency ENT surgery,
* Refused to participate in the research,
* Did not sign the Informed Consent Form,
* Have a physical problem that prevents the application of acupressure to EX-HN3 (Yintang), LI4 and HT7 points,
* Diagnosed with anxiety, panic attacks and taking medication for anxiety,
* Previous surgical experience,
* Under 18 and over 65,
* People with vision, hearing and perception problems,
* unable to read and write Turkish,
* Have any problem that prevents them from communicating cognitively, emotionally and verbally,
* Experience in acupressure,
* Patients who have received sedative medication before surgical intervention didn't be included in the study.

Exclusion Criteria:

* Emergency ENT surgery,
* Refused to participate in the research,
* Did not sign the Informed Consent Form,
* Diagnosed with anxiety, panic attacks and taking medication for anxiety,
* Previous surgical experience
* Under 18 and over 65,
* People with vision, hearing and perception problems,
* unable to read and write Turkish,
* Have any problem that prevents them from communicating cognitively, emotionally and verbally,
* Experience in acupressure,
* Patients who have received sedative medication before surgical intervention didn't be included in the study.
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment

This is an open-label, clinical pharmacology study to evaluate the safety and PK of MRA in patients with RA with Renal Impairment.


Eligibility Criteria:
Inclusion criteria

* Patients who are diagnosed with RA according to the 1987 ACR (American College of Rheumatology) classification criteria
* Patients with RA at least 6 months prior to enrollment
* Patients with a creatinine clearance not less than 10 mL/min but no higher than 80 mL/min

Exclusion criteria

* Patients with Class IV Steinbrocker functional impairment at enrollment
* Patients who are undergoing dialysis
* Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept, and have been receiving treatment with leflunomide, within 12 weeks before treatment with the investigational product
Feasibility and Usability of a Virtual Reality System

Intellectual disability (ID) and autism spectrum disorder (ASD) are often co-occurring neurodevelopmental disorders that require composite intervention. However, standardized rehabilitation programs presented several limitations due to behavioral problems and poor engagement in proposed activity. The Virtual Reality Rehabilitation System (VRRS) is a medical device is recognized as one of the most advanced systems to rehabilitate patients with motor, cognitive, linguistic and behavioral disorders. The use of VRRS offers the opportunity to adapting task parameters according to the patient's performance and the virtual system increases engagement and avoids boredom and frustration. the patients underwent a two months experimental intervention integrated into the regular activity of a semi-residential center for autistic adolescents and young adults.


Eligibility Criteria:
Inclusion criteria:

* subjects diagnosed with ASD and ID, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
* age between 6 and 40 years;
* cognitive level \<65 Intellectual Quotient
* signed informed consent

Exclusion criteria:

* subjects without diagnosis of ASD and ID, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
* age not between 6 and 40 years;
* cognitive level \>65 Intellectual Quotient
* unsigned informed consent